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Ferritin plays a central role in iron metabolism and is made of 24 subunits of 2 types: heavy chain and light 
chain. The ferritin heavy chain (FtH) has ferroxidase activity that is required for iron incorporation and limit-
ing toxicity. The purpose of this study was to investigate the role of FtH in acute kidney injury (AKI) and renal 
iron handling by using proximal tubule–specific FtH-knockout mice (FtHPT–/– mice). FtHPT–/– mice had signifi-
cant mortality, worse structural and functional renal injury, and increased levels of apoptosis in rhabdomy-
olysis and cisplatin-induced AKI, despite significantly higher expression of heme oxygenase-1, an antioxidant 
and cytoprotective enzyme. While expression of divalent metal transporter-1 was unaffected, expression of 
ferroportin (FPN) was significantly lower under both basal and rhabdomyolysis-induced AKI in FtHPT–/– mice. 
Apical localization of FPN was disrupted after AKI to a diffuse cytosolic and basolateral pattern. FtH, regard-
less of iron content and ferroxidase activity, induced FPN. Interestingly, urinary levels of the iron acceptor pro-
teins neutrophil gelatinase–associated lipocalin, hemopexin, and transferrin were increased in FtHPT–/– mice 
after AKI. These results underscore the protective role of FtH and reveal the critical role of proximal tubule 
FtH in iron trafficking in AKI.
Introduction
Acute kidney injury (AKI) remains a major clinical challenge, with 
significant attributable morbidity and mortality (1). The pathogen-
esis of AKI is remarkably complex due to numerous insults as well 
as the involvement of many independent and overlapping patho-
physiological pathways. Given its anatomy and intricate function, 
the proximal tubule segment of the nephron is predictably the 
most susceptible to various forms of injury. Multiple molecular 
mechanisms have been proposed that potentiate and/or aggravate 
AKI, but ROS-induced kidney injury is recognized as one of the key 
mediators (2–8). In support of this premise, studies have provid-
ed strong evidence that upregulation of endogenous antioxidant 
defense systems, such as induction of the heme oxygenase-1 (HO-1) 
enzyme, mitigates AKI in different injury settings (4).
Once liberated into a free catalytic form, iron is an essential 
mediator of injury that can instigate and maintain generation of 
ROS that may damage literally all macromolecular cellular com-
partments. This property is attributed to the ability of iron to 
readily accept and donate electrons. Although potentially toxic 
in its free catalytic form, the very same redox potential of iron 
makes it a requisite for life for almost all organisms. Hence, to 
maintain a delicate balance among homeostatic needs and to 
prevent potential detrimental effects, multiple highly synchro-
nized regulatory mechanisms that function at both systemic 
and cellular levels have evolved. An intriguing, highly conserved 
molecule that has the capacity of sequestering large amounts of 
iron (up to 4,500 atoms) in a safe, soluble, and bioavailable form 
is ferritin. The major regulator of intracellular iron, ferritin is 
made of 24 subunits of 2 distinct types: heavy chain (H-ferritin; 
FtH) and light chain (L-ferritin; FtL) (9). Importantly, FtH has 
ferroxidase activity, which catalyzes the conversion of the ferrous 
form (Fe2+) to the ferric form (Fe3+), allowing the safe incorpora-
tion of iron into the ferritin shell and thereby attenuating par-
ticipation of free iron in ROS generation. Previous studies have 
demonstrated that induction of HO-1 is coupled to upregulation 
of ferritin — the latter a response to sequestration of iron from 
the HO-1 catalyzed reaction (8, 10). Interestingly, FtH, which 
was traditionally recognized as a cytosolic protein, has been 
described in the mitochondria and the nucleus, which highlights 
its function at diverse cellular organelles (11, 12). Furthermore, 
recent data suggest that FtH is also involved in functions that are 
not primarily linked to iron sequestration, such as promotion of 
angiogenesis and attenuation of osteoblastic differentiation of 
vascular smooth muscle cells (13, 14).
The detrimental role of iron in AKI has been demonstrated 
in multiple models of AKI. Furthermore, chelation of iron has 
been shown to be protective in both in vitro and in vivo mod-
els of AKI (2, 3, 5, 15–21). However, despite the recognition of 
iron as a culprit in AKI, little is known about the nephron’s 
response — to minimize the availability and enhance the redis-
tribution of iron — that could potentially alleviate injury. 
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Additionally, whereas the contribution of the intestine, liver, 
and reticuloendothelial system in systemic iron homeostasis 
is extensively studied, very little is known about the extent of 
renal involvement in such orchestration (22–28). Considering 
the wealth of knowledge regarding renal handling of assorted 
molecules and electrolytes, animal models that would enable 
deciphering the role of the kidney in systemic iron homeostasis 
and iron trafficking during AKI are timely and may provide new 
avenues for potential therapies.
To address these questions, we generated renal proximal tubule–
specific FtH–deleted mice (referred to herein as FtHPT–/– mice) to 
examine the role of FtH in AKI and, more notably, to study the kid-
ney’s response to iron trafficking at the renal cellular level under 
pathological conditions.
Results
Characterization of FtHPT–/– mice. Renal proximal tubule–specific FtH 
deletion was achieved by crossing FtHlox/lox mice (27) with PEPCK-
Cre mice (29). Notably, the Cre mice were generated using a 
mutated PEPCK promoter, resulting in minimal hepatocyte activ-
ity (30). FtHPT–/– mice were born at the expected Mendelian ratio, 
were viable and fertile, and did not manifest any apparent abnor-
malities during 6 months of observation. In addition, analysis of 
kidney sections from these mice did not demonstrate any patho-
logical findings (data not shown). FtHlox/lox mice — homozygous 
for the floxed allele and expressing FtH in the proximal tubules 
— were used as controls (referred to herein as FtHPT+/+ mice). The 
recombination event by Cre was confirmed by PCR using genomic 
DNA with specific primers (Table 1). The recombined product was 
detected in the kidneys and, to a lesser extent, the livers of FtHPT–/– 
mice. No recombined product was detected in any of the other 
organs tested, including heart, spleen, and lung (Figure 1A). This 
was also validated by mRNA expression analysis of FtHPT+/+ and 
FtHPT–/– organs, with a significant decrease in FtH expression in 
only the kidneys of FtHPT–/– mice (Figure 1B). There were no signifi-
cant differences in mRNA and protein expression of FtH in whole-
liver lysates from FtHPT+/+ and FtHPT–/– mice (Figure 1, B and C). 
Staining for FtH was detectable in the liver, except in a subset 
of periportal hepatocytes, in which expression was decreased 
in FtHPT–/– mice (Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI67867DS1). 
These observations are consistent with the original description of 
the PEPCK-Cre reporter mice (31). Western blot analysis validated 
deletion of FtH only in the kidneys of FtHPT–/– mice, with no com-
pensatory increase in FtL expression (Figure 1C). Additionally, 
under basal conditions, deletion of FtH in the proximal tubules 
was not associated with significant alteration of total iron-binding 
capacity or serum iron (Figure 1, D and E). Furthermore, while the 
Figure 1
Characterization of FtHPT–/– mice. (A) PCR analysis, performed on genomic DNA from organs, for the presence of the floxed (419 bp) and deleted 
(530 bp) FtH allele. (B) FtH mRNA expression in the organs of FtHPT+/+ and FtHPT–/– mice, analyzed by real-time PCR. Results were normalized to 
GAPDH and expressed as fold change compared with FtHPT+/+. Data are mean ± SEM. *P < 0.001 vs. FtHPT+/+. (C) Western blot was performed on 
organ lysates for FtH expression. Membranes were stripped and reprobed for GAPDH as a loading control. Native gels were run for the detection 
of FtL, and coomassie stain served as a loading control. (D and E) Total iron-binding capacity (TIBC; D) and total iron levels (E) in the serum of 
FtHPT+/+ and FtHPT–/– mice. Data are mean ± SEM. No statistical difference was present between groups. (F) Immunohistochemical staining on 
serial kidney sections from FtHPT+/+ and FtHPT–/– mice for FtH and the proximal tubule marker lotus lectin. For each experiment, n = 4–8 per group.
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proximal tubules of FtHPT+/+ mice demonstrated colocalization of 
FtH expression and the proximal tubule marker lotus lectin after 
glycerol administration, there was no FtH expression in FtHPT–/– 
proximal tubules (Figure 1F).
Proximal tubule FtH deletion aggravates heme-mediated AKI. Given 
the significance of FtH in the safe sequestration of the potentially 
detrimental iron, we hypothesized that deletion of FtH in proxi-
mal tubules of the kidney would aggravate heme-mediated AKI in a 
model of glycerol-induced rhabdomyolysis. To this end, we demon-
strated that glycerol administration to FtHPT–/– mice led to substan-
tial mortality compared with FtHPT+/+ controls (Figure 2A). To deter-
mine the functional significance of FtH deletion in proximal tubules, 
we measured serum creatinine 24 hours after glycerol administra-
tion. Whereas there was no significant difference in creatinine levels 
after saline administration, the rise in serum creatinine in response 
to rhabdomyolysis-induced AKI was significantly higher in FtHPT–/– 
versus FtHPT+/+ mice (Figure 2B). In addition, although serum iron 
levels were not significantly different between the groups (Figure 2C), 
serum ferritin levels were markedly higher in FtHPT–/– versus FtHPT+/+ 
mice after glycerol administration (Figure 2D). Renal histology fur-
ther corroborated the protective role of FtH in AKI, as evidenced by 
the higher number of tubular casts and necrotic tubules and the loss 
of proximal tubule brush border in FtHPT–/– kidneys after glycerol 
administration (Figure 2E). In order to evaluate the role of ferritin as 
a protective response to AKI, we further examined the kidneys for FtL 
and FtH expression, both of which increased markedly after glycerol 
administration (Figure 2, F and G). FtH levels were significantly lower 
in FtHPT–/– mice (Figure 2G). This was also confirmed by Western blot 
on whole kidney lysates from saline- and glycerol-treated animals 
(Figure 2, H and I). In addition, we found that expression of cleaved 
caspase-3, a marker of apoptosis, was higher in FtHPT–/– kidneys after 
rhabdomyolysis (Figure 2, H and J).
Figure 2
Ablation of FtH in the proximal tubules worsens heme-mediated AKI. (A) FtHPT+/+ and FtHPT–/– mice were administered glycerol, and survival 
was monitored up to 6 days (n = 10 per group). (B) Serum creatinine was measured 24 hours after saline or glycerol administration. Data are 
mean ± SEM. *P < 0.01 vs. glycerol-treated FtHPT+/+. (C) Total iron levels in the serum of glycerol-treated FtHPT+/+ and FtHPT–/– mice. (D) Serum 
ferritin was measured 24 hours after saline or glycerol administration. *P < 0.01 vs. glycerol-treated FtHPT+/+. (E) Representative PAS staining of 
cortex and medulla of glycerol-treated FtHPT+/+ and FtHPT–/– mice. Scale bar: 100 μm. (F and G) FtL and FtH mRNA expression was analyzed by 
real-time PCR in total RNA extracts of kidneys from saline- or glycerol-treated FtHPT+/+ and FtHPT–/– mice. Data are expressed as fold change in 
ferritin expression compared with saline-treated FtHPT+/+ mice (n = 3 per group). *P < 0.01. (H) FtH and cleaved caspase-3 expression was veri-
fied by Western blot. Blots were stripped and reprobed for GAPDH. (I and J) Expression of the indicated proteins in the kidneys was analyzed by 
densitometry, normalized to GAPDH, and expressed as mean ± SEM. *P < 0.05 vs. glycerol-treated FtHPT+/+. 
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Proximal tubule FtH deletion exacerbates non–heme-mediated AKI. 
To elucidate the protective role of FtH in a primarily non–heme-
dependent injury setting, we used another model of AKI, namely 
cisplatin nephrotoxicity. At 3 days after cisplatin administration, 
FtHPT–/– mice had significantly higher serum creatinine and ferritin 
levels, which were associated with a significant decrease in serum 
iron levels, compared with FtHPT+/+ mice (Figure 3, A–C). Concur-
rently, FtHPT–/– mice exhibited worse structural architecture, with 
a substantial number of casts and necrotic tubules (Figure 3D). 
Consistent with previous observations (8), FtH was induced after 
cisplatin administration in FtHPT+/+ mice, but this was significantly 
lower in FtHPT–/– mice (Figure 3, E and F). Western blot analysis 
revealed higher cleaved caspase-3 expression in FtHPT–/– kidneys 
compared with cisplatin-treated FtHPT+/+ mice (Figure 3, E and H). 
Interestingly, we found that expression of HO-1, a cytoprotective 
enzyme indispensable for protection against both glycerol- and 
cisplatin-induced kidney injury, was significantly higher under 
injury settings (Figure 3E), but nonetheless was unable to pro-
vide renal protection in the absence of FtH. Taken together, these 
results indicate that proximal tubule FtH expression and induc-
tion plays an important protective role in different settings of AKI.
Urinary iron acceptor proteins are increased in the absence of proxi-
mal tubular FtH. To investigate the response of the nephron to 
increased levels of iron, we measured levels of urinary catalytic 
iron. While there was a significant increase in catalytic iron levels 
after glycerol administration, such increment was not significant-
ly altered by proximal tubule FtH ablation (Figure 4A). However, 
total urinary iron levels tended to be higher in the FtHPT–/– mice 
after glycerol-induced rhabdomyolysis (Figure 4B). In light of the 
evidence that total urinary iron was higher while there was no dif-
ference in catalytic iron, we sought to determine the levels of neu-
trophil gelatinase-associated lipocalin (NGAL; an iron siderophore 
Figure 3
Cisplatin nephrotoxicity is exacerbated in the absence of proximal tubule FtH expression. Mice were administered saline or cisplatin for 
3 days (n = 3–10 per group). (A) Serum creatinine, measured at time of harvest and expressed as mg/dl. *P < 0.05 vs cisplatin-treated FtHPT+/+. 
(B) Total iron levels in the serum of FtHPT+/+ and FtHPT–/– mice after cisplatin administration. *P < 0.05 vs. FtHPT+/+. (C) Serum ferritin in cisplatin-
treated FtHPT+/+ and FtHPT–/– mice. *P < 0.01 vs FtHPT+/+. (D) Representative PAS staining of cortex and medulla of saline- or cisplatin-treated 
FtHPT+/+ and FtHPT–/– mice. Scale bar: 100 μm. (E) FtH, cleaved caspase-3, and HO-1 expression was verified by Western blot. Blots were 
stripped and reprobed for GAPDH. (F–H) Expression of the indicated proteins in the kidneys was analyzed by densitometry, normalized to 
GAPDH, and expressed as mean ± SEM. *P < 0.05, #P < 0.01 vs. cisplatin-treated FtHPT+/+.
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that increases after AKI), transferrin, and hemopexin as potential 
iron acceptor proteins. As shown in Figure 4C and Supplemental 
Figure 2, A and B, hemopexin, NGAL, and transferrin levels were 
significantly higher in the urine from FtHPT–/– mice with rhabdo-
myolysis, both with and without normalization of these levels to 
urine creatinine. After cisplatin administration, all 3 urinary iron 
acceptors tended to be higher in FtHPT–/– than in FtHPT+/+ mice 
(Figure 4D and Supplemental Figure 2D). However, after normal-
ization to creatinine, only transferrin levels were significantly high-
er (Figure 4D). Under basal conditions, levels of NGAL (FtHPT+/+, 
2.4 ± 1 ng/mg Cr; FtHPT–/–, 1.6 ± 0.1 ng/mg Cr), hemopexin (FtHPT+/+, 
3.17 ± 0.3 ng/mg Cr; FtHPT–/–, 3.8 ± 0.1 ng/mg Cr), and transfer-
rin (FtHPT+/+, 0.96 ± 0.16 ng/mg Cr; FtHPT–/–, 1.2 ± 0.13 ng/mg Cr) 
were not signif icantly different between the groups 
(n = 5–8 per group). These results suggest that the kidney plays an 
important role in iron trafficking and homeostasis during injury.
FtH modulates expression of FPN, but not DMT-1, during AKI. We next 
examined the expression of the known iron-trafficking proteins 
divalent metal transporter 1 (DMT-1) and ferroportin (FPN) in 
response to injury. DMT-1 was induced after AKI in both FtHPT+/+ 
and FtHPT–/– kidneys to similar levels in the cisplatin and rhab-
domyolysis models (Supplemental Figure 3A). In contrast, we 
found that while FPN expression was significantly induced in 
the cortex and medulla after rhabdomyolysis-induced AKI, both 
mRNA and protein levels of FPN were markedly lower in FtHPT–/– 
mice compared with their FtHPT+/+ littermates under both basal 
and injury settings (Figure 5, A and B). Of note, there was no 
detectable change in hepatic expression of FPN in FtHPT–/– mice 
(Supplemental Figure 1). Under basal conditions, FPN was pre-
dominantly expressed in the apical brush border region of the 
proximal tubules in the outer stripe of the medulla and inner corti-
cal areas of the kidney (Figure 5, C–E, and Supplemental Figure 4, 
A and B). The brush border localization of FPN in renal proximal 
tubules was also confirmed by immunogold electron microscopy 
(Figure 5C). Occasional gold particles were found in the mitochon-
dria and cytoplasm of renal proximal tubules, whereas experimen-
tal controls without the primary antibody did not demonstrate 
any nonspecific immunogold localization (Supplemental Figure 4, 
C and D). A few renal tubules in the outer cortex of uninjured kid-
neys showed cytoplasmic and basolateral FPN expression (Supple-
mental Figure 4, A and B). Upon injury, the apical localization of 
FPN in the basal state was markedly altered to a diffuse cytosolic 
and basolateral pattern and extended to the outer cortex of the 
kidney (Figure 5, D and E). In addition, after injury, induction of 
FtH was accompanied by a substantial increase in FPN expression 
in the proximal tubules of FtHPT+/+ mice (Figure 5, B and D). Serial 
sections revealed overlap in staining of FtH and FPN in the same 
renal tubules (Figure 5E).
FtH regulates FPN expression in renal proximal tubules. Upon further 
investigation of the relationship between FtH and FPN, we deter-
mined that HO-1–/– mice had increased FtH expression along with 
increased FPN levels in the kidneys (Figure 6, A and B). Such co-
induction of FPN and FtH may explain the aberrant iron deposi-
tion in proximal tubules of HO-1–/– kidneys. To further decipher 
the mechanism of FPN modulation by FtH, we isolated proxi-
mal tubular cells from wild-type mice and administered apofer-
ritin (ferritin shell, devoid of iron). FPN expression was induced 
after apoferritin administration at the mRNA and protein levels 
(Figure 6, C and D). As apoferritin is a combination of both 
FtH and FtL, we treated cells with recombinant FtH alone and 
Figure 4
Increased excretion of urinary iron and iron acceptor proteins in 
FtHPT–/– mice after AKI. (A) Catalytic iron was measured in the 
urine of saline- or glycerol-treated FtHPT+/+ and FtHPT–/– mice. 
Data were normalized to urine creatinine levels and expressed 
as nanomoles of iron per milligram creatinine. *P < 0.05 vs. 
respective saline control. (B) Total iron content was measured 
in the urine of glycerol-treated FtHPT+/+ and FtHPT–/– mice. Data 
were normalized to urine creatinine and expressed as micro-
gram iron per milligram creatinine. (C and D) Hemopexin, 
NGAL, and transferrin were measured by ELISA in the urine 
from glycerol- (C) or cisplatin-treated (D) FtHPT+/+ and FtHPT–/– 
mice. Data were normalized to urine creatinine and expressed 
as microgram per milligram creatinine. *P < 0.05 vs. FtHPT+/+.
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observed an increase in FPN expression. Furthermore, a mutant 
form of ferritin lacking ferroxidase activity (referred to herein as 
FtH-M) was also able to induce FPN (Figure 6E). These results 
demonstrated ferritin-mediated induction of FPN in renal proxi-
mal tubular cells and corroborate our in vivo findings of increased 
FPN expression in FtHPT+/+ kidneys after AKI (Figure 5B). Con-
versely, the absence of FtH in FtHPT–/– kidneys was associated with 
decreased FPN expression (Figure 5B).
We further assessed the ability of proximal tubular cells to medi-
ate iron trafficking via a FPN-dependent mechanism. Cells were 
plated on Transwell filters, and polarization was confirmed by stain-
ing cells for ZO-1, an apical peripheral membrane protein associated 
with tight junctions (Figure 6F). Consistent with previous studies 
using hepatocytes (32), hepcidin decreased the expression of FPN 
in proximal tubular epithelial cells in a time-dependent manner 
(Figure 6G), and pretreatment with hepcidin significantly reduced 
uptake of apical radiolabeled iron chloride (55Fe) by approximately 
35% (Figure 6H), which suggests that iron import in renal proximal 
tubular cells is mediated, at least in part, via FPN.
Discussion
In this study, we found that FtHPT–/– mice, with conditional dele-
tion of FtH in renal proximal tubules, demonstrated increased 
susceptibility to injury manifested by worse renal structural and 
functional measures in 2 different models of AKI: rhabdomyolysis 
and cisplatin nephrotoxicity. Our results validated that the proxi-
mal tubules are the major site of FtH expression and verified the 
detrimental role of iron in AKI. Moreover, we found that while FtH 
ablation was accompanied by decreased FPN expression in vivo, 
addition of apoferritin to proximal tubular cells in vitro resulted 
in a significant increase in FPN expression at both mRNA and 
protein levels. Furthermore, we demonstrated that the ferroxidase 
Figure 5
FtH modulates FPN expression during AKI. (A) FPN expression in FtHPT+/+ and FtHPT–/– kidneys after saline or glycerol administration, examined by 
real-time PCR. Data were normalized to GAPDH and expressed as fold change in FPN mRNA relative to saline-treated FtHPT+/+ (n = 3–5 per group). 
*P < 0.05. (B) FPN, HO-1, and FtH expression in the cortex and medulla of FtHPT+/+ and FtHPT–/– mice, analyzed by Western blot. Membranes were 
probed for GAPDH as a loading control. (C) Immunohistochemical staining of a kidney section for FPN and immunoelectron micrograph of a proximal 
tubule in the outer stripe of the outer medulla, illustrating FPN localization to the brush border on the apical surface. Arrows indicate gold particles. 
(D) Immunohistochemical staining showing differential expression of FPN in the proximal tubules of saline- and glycerol-treated FtHPT+/+ mice. 
(E) Immunohistochemical staining of serial kidney sections for FPN and FtH after administration of saline or glycerol, as well as magnified views 
showing their colocalization in the proximal tubule (right, enlarged ×10). Scale bars: 500 nm (C); 500 nm (C, inset); 100 μm (D and E).
Downloaded on October  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/67867
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 10   October 2013 4429
activity of FtH was not essential in upregulation of FPN expres-
sion. Our results also highlighted that loss of FtH in the proximal 
tubules did not lead to a compensatory increase in FtL levels, as 
has been observed in the liver (27). This suggests that while the 
kidney is actively involved in iron trafficking and reabsorption, it 
is not a major site of iron storage under physiological conditions.
The toxicity of excess iron deposition in different tissues has 
been recognized in clinical conditions, such as systemic hemo-
chromatosis. However, the implications of catalytic iron in AKI 
pathogenesis in the absence of systemic iron overload have only 
recently begun to emerge. Several studies have reported that iron 
is deleterious in multiple settings of AKI, such as rhabdomyolysis, 
nephrotoxicity (cisplatin and gentamycin), ischemia/reperfusion 
injury, and contrast-induced AKI. Furthermore, iron chelation 
with deferoxamine has been reported to provide protection and 
significantly improve the severity and outcomes of AKI (2, 3, 5, 
15–21, 33). Additionally, other endogenous proteins involved in 
iron regulation and chelation, such as hepcidin and NGAL, have 
been shown to protect against AKI (21, 34–37). Our current find-
ings corroborate the injurious role of iron in AKI and delineate 
the renal proximal tubule as the major site of iron-induced injury.
The nephron has the capacity to limit the deleterious effects of 
AKI via different mechanisms. HO-1 is an enzyme that is rapidly 
induced in response to a variety of injurious stimuli, providing 
potent antioxidant, antiinflammatory, and antiapoptotic effects. 
The protective effects of HO-1 have been extensively studied, and 
its induction is known to be beneficial in a wide range of AKI 
settings (4, 7). Additionally, HO-1 induction was coupled to 
increased ferritin expression during AKI (8, 10). Consistent with 
recent findings in the intestine, our results revealed that dele-
tion of FtH was accompanied by a significant increase in HO-1 
expression under both basal and AKI conditions, presumably as 
an antioxidant compensatory mechanism (24). However, despite 
significantly higher levels of HO-1 in FtHPT–/– kidneys, AKI sever-
ity was remarkably higher in these animals compared with their 
control littermates. These findings demonstrated that the benefi-
cial effects of HO-1 are codependent on FtH and underscored the 
importance of FtH induction as a key antioxidant mechanism in 
proximal tubules during AKI.
Control of iron metabolism is a meticulously regulated process to 
provide iron when needed and curtail its toxicity by restricting avail-
ability of free iron. At the systemic level, this is mainly achieved by 
vigilant pathways of iron absorption and recycling, namely, release 
of iron from macrophages, release of stored iron from hepatocytes, 
and absorption of dietary iron by duodenal enterocytes (23, 38, 39). 
In this regard, the only known membrane iron transporter, FPN, is 
at the epicenter of this axis, and its aberrant expression has previ-
ously been shown to cause derangements in systemic iron homeo-
stasis (40, 41). Several studies have demonstrated that expression 
of FPN is regulated at multiple levels, including a posttranslational 
mechanism by hepcidin, a generally accepted major pathway for 
FPN regulation. Hepcidin is primarily produced and secreted by 
hepatocytes and functions by directly binding to FPN, causing its 
internalization and degradation in lysosomes (25, 40–42).
Figure 6
FtH regulates FPN expression in renal proximal tubules. 
(A) Whole kidney lysates from HO-1+/+ and HO-1–/– mice 
were analyzed for FPN, HO-1, and FtH levels by Western 
blot. Membranes were reprobed for GAPDH to demonstrate 
equal loading. (B) Kidney FPN and FtH expression was ana-
lyzed by densitometry analysis, normalized to GAPDH, and 
expressed as mean ± SEM. *P < 0.05 vs HO-1+/+. (C) FtHPT+/+ 
proximal tubular epithelial cells were treated in vitro with 
apoferritin for 8 hours and analyzed for FPN expression by 
real-time PCR. Data are expressed as fold change relative to 
vehicle-treated cells. *P < 0.05. (D) Proximal tubular epithe-
lial cells were treated with the indicated doses of apoferritin 
for 16 hours and analyzed for FPN and FtH expression by 
Western blot. GAPDH served as a loading control. (E) Proxi-
mal tubular epithelial cells were treated with vehicle, FtH, or 
FtH-M for 16 hours and analyzed for FPN and FtH expres-
sion by Western blot. GAPDH served as a loading control. 
Results are representative of 3 independent experiments. 
(F) Immunocytochemistry for ZO-1 expression on cells grown 
on Transwell filters, confirming polarization. Original magnifi-
cation, ×180. (G) Proximal tubular epithelial cells were treated 
with hepcidin for the indicated times and analyzed for FPN 
expression by Western blot. (H) Proximal tubular cells grown 
on Transwell filters were pretreated with vehicle (control) or 
hepcidin for 48 hours, 55Fe was administered to the apical 
compartment for 2 hours, and cellular 55Fe levels were mea-
sured and expressed as picomoles of iron per milligram pro-
tein. *P < 0.05 vs. control.
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Despite extensive research in the field of iron metabolism, little 
is known about the contributing role of FPN in the kidney. Emerg-
ing data, however, suggest that the kidney may be more exten-
sively involved in iron metabolism than initially proposed. For 
instance, studies have revealed that multiple proteins involved in 
iron metabolism are expressed in the kidney, including hepcidin, 
FPN, and DMT-1 (43–47). Intriguingly, we found that deletion 
of FtH did not affect the expression of DMT-1 (expressed in late 
endosome/lysosome membranes of tubular cells), but was accom-
panied with diminution of FPN expression, in FtHPT–/– kidneys. 
This decrease was observed at both mRNA and protein levels, sug-
gesting the correlation to be hepcidin independent. Furthermore, 
we observed that rhabdomyolysis-induced AKI was associated with 
significant induction of FPN expression in FtHPT+/+ kidneys and, 
to a lesser extent, FtHPT–/– kidneys. Under normal conditions, FPN 
was predominantly expressed at the apical side of the proximal 
tubule. However, after AKI, FPN was redistributed to a cytosolic 
and basolateral pattern in proximal tubules. To clarify whether 
FPN expression is mediated by iron and/or ferritin, we used apo-
ferritin and recombinant FtH and FtH-M, the latter of which lacks 
ferroxidase activity. These experiments revealed that apoferritin 
and FtH (both devoid of iron) significantly increased FPN expres-
sion. In addition, our observations suggest that the ferroxidase 
activity of FtH was not required in this regulatory mechanism. 
Therefore, we report for the first time a novel function for FtH in 
the context of regulation of FPN expression.
The mechanism of such regulation may provide new avenues for 
better understanding of molecular and systemic iron homeostasis 
and will require further investigation. FtH is capable of inducing 
several genes, including iNOS and IL-1β, through modulation of 
MAPK and NF-κB signaling pathways (48). IL-1β–dependent tran-
scriptional induction of FPN also requires activation of the NF-κB 
and MAPK pathways (49). Another plausible mechanism may 
involve the ability of FtH to translocate to the nucleus. While FtH 
was traditionally regarded as a cytoplasmic protein, its presence in 
nuclei of different cell types has been previously described (50–52). 
Furthermore, FtH has been shown to regulate transcription of cer-
tain genes, including the human β-globin gene by binding to the 
highly conserved CAGTGC motif in the promoter (52). The local-
ization of FtH to the nucleus, and its involvement in transcription 
via modulation of signal transduction and/or regulation of signal-
ing pathways, are potential mechanisms by which FtH may regu-
late the transcription of FPN. We also suggest that these findings 
are quite relevant to perceptions regarding the fate of iron released 
from the heme tetrapyrrole ring by HO in the injured kidney. Such 
iron is conventionally handled by either 1 of 2 discrete, noninter-
acting pathways, namely, sequestration by ferritin or trafficking 
by FPN. Our present data demonstrated that these pathways are 
indeed linked because of the inductive effect of ferritin on FPN. This 
inductive effect makes for more efficient cellular handling of iron, a 
potentially cytotoxic species, especially in the acutely injured kidney.
Although FPN expression was lower in FtHPT–/– kidneys under 
both basal and AKI conditions, urinary catalytic iron levels were not 
significantly different between the 2 groups. These results could be 
explained by higher levels of urinary iron-binding proteins, including 
NGAL, hemopexin, and transferrin, in FtHPT–/– mice. The presence 
of iron acceptor proteins in the urine under uninjured conditions 
may imply that small amounts of such proteins are filtered, and their 
subsequent increase after AKI reflects the extent of tubular injury 
and hence decreased reabsorption. This may, however, serve as a 
protective phenomenon that would minimize the level of intratubu-
lar free iron released into the tubules after cell injury and increased 
delivery. In addition, serum iron levels were significantly lower in 
FtHPT–/– mice that received cisplatin, but were not different between 
the groups after glycerol administration. This highlights the differ-
ence in the mode of injury inflicted by these models of injury, where 
rhabdomyolysis predominantly imposes a large heme-iron burden.
Another observation that supports a role of the kidney in system-
ic iron homeostasis comes from HO-1–/– mice. Although it is well 
known that HO-1 deficiency leads to iron overload in the kidney, 
particularly in proximal tubular cells, the precise mechanism of 
this finding, and whether it may explain the microcytic anemia that 
accompanies HO-1 deficiency, has not been investigated (48–50). 
Interestingly, FPN colocalized with FtH, which suggests a role for 
this protein in iron import. While further studies are required to 
elaborately substantiate the mechanism of iron overload in HO-1–/– 
kidneys and its potential involvement in iron deficiency anemia, our 
results suggest that the higher levels of FtH expression and the sub-
sequent increase in FPN may explain the deranged iron deposition 
in kidneys of these animals. We demonstrated that under basal con-
Figure 7
Regulation of iron homeostasis by FtH in the proximal tubules of the 
kidney. Under basal conditions, FPN is expressed on the apical sur-
face of the proximal tubules, which facilitates iron reabsorption and 
safe sequestration by ferritin. AKI induces the expression of FtH and 
HO-1, and FtH in turn increases expression and redistribution of FPN 
throughout the tubule and toward the basolateral side. In the absence 
of FtH, FPN induction after AKI is reduced and may potentially impair 
iron reabsorption. Although HO-1 is substantially increased, these 
cells are more susceptible to injury and apoptosis, which suggests that 
HO-1–mediated protection is dependent on FtH.
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ditions, FPN was expressed on the apical membrane of the proximal 
tubules and facilitated iron reabsorption, which was significantly 
reduced by hepcidin pretreatment. However, renal iron uptake is not 
only dependent on FPN, but may likely involve other proteins, such 
as DMT-1 and transferrin (44, 47, 51).
FtH induction during AKI increases FPN expression and redis-
tributes FPN throughout the tubule and toward the basolateral 
side, perhaps in an attempt to return iron to the systemic circula-
tion. This notion is supported by a decrease in FPN expression 
in FtHPT–/– mice, which is accompanied by increased urinary iron 
excretion (Figure 7). We hypothesize that FPN imports any free 
iron that may have been filtered into the proximal tubule, thereby 
preventing the loss of iron and preserving iron homeostasis; the 
imported Fe2+ may be converted to Fe3+ by FtH in the intracellular 
space. However, during AKI and after intracellular iron increases, 
the directionality may change to minimize injury. It has previously 
been reported that proximal tubules are capable of FtH secretion, a 
function that may provide ferroxidase activity within the lumen to 
convert Fe2+ to Fe3+ (52). Our model thus posits bidirectionality in 
the conveyance of iron by FPN, depending on the presence of kid-
ney injury: in states of health, there is net cellular import of iron 
by FPN into the proximal tubule, whereas in the acutely injured 
kidney, net extracellular export by FPN mitigates elevations in cel-
lular iron that may otherwise occur.
In conclusion, conditional deletion of FtH in kidney proximal 
tubules led to significantly worse structural and functional AKI. 
Our results highlighted the key determinant role of iron in 2 models 
of AKI. Furthermore, our evidence identified proximal tubule FtH 
as a major regulator of iron and FPN, a function that may provide 
important clues to derangements in iron homeostasis commonly 
observed with kidney dysfunction. Based on our observations, we 
suggest that the kidney plays a crucial role in iron trafficking, par-
ticularly during injury, and that additional studies are warranted to 
gain further insights on the meticulous axis of iron metabolism and 
involvement of the kidney in this process.
Methods
Animals. The FtHPT+/+ mice used in this study were previously described FtH-
floxed mice (27). PEPCK Cre transgenic mice that express Cre recombinase 
primarily in the proximal tubules of the kidney were provided by V. Haase 
(Vanderbilt University, Nashville, Tennessee, USA; ref. 29). All FtH transgenic 
mice used in this study were on a predominantly C57BL/6 background. Adult 
male mice (8 weeks of age) were provided acidified water (0.3 M ammonium 
chloride) for 1 week to enhance PEPCK promoter activity in the kidney. HO-1+/+ 
and HO-1–/– male mice (24–26 weeks of age) were used in this study (50).
Confirmation of FtH deletion by genomic DNA PCR. Genomic DNA was isolat-
ed from the tail, kidney, heart, spleen, liver, and lung of FtHPT+/+ and FtHPT–/– 
mice using Puregene Core Kit A (Qiagen) according to the manufacturer’s 
instructions. PCR was performed on the genomic DNA to verify the presence 
of the transgene using specific primers (Table 1). The floxed allele amplicon 
was identified as 419 bp, while the Cre-mediated deleted allele was 530 bp.
Quantification of mRNA expression. Total RNA was isolated from cells or 
tissues by TRIzol (Invitrogen), and SYBR Green–based real-time PCR was 
performed on cDNA product generated from total RNA (Qiagen). Relative 
mRNA expression was quantified using the ΔΔCt method and normalized 
to GAPDH mRNA as an internal control. See Table 1 for real-time primers 
used. All reactions were performed in triplicate, and specificity was moni-
tored using melting curve analysis.
Cisplatin nephrotoxicity. Cisplatin injury was induced in age-matched 
FtHPT+/+ and FtHPT–/– mice (10–14 weeks of age) as described previously 
(53). Briefly, mice were administered cisplatin (1.0 mg/ml solution in 
sterile normal saline) or vehicle (normal saline) at 20 mg/kg body weight 
by a single intraperitoneal injection. All animals were sacrificed 72 hours 
after injection, and kidneys were harvested for staining or protein analy-
sis. Blood was collected via cardiac puncture, and serum was isolated for 
creatinine measurement by LC-MS/MS (54).
Rhabdomyolysis. Glycerol model of rhabdomyolysis was induced in age-
matched FtHPT+/+ and FtHPT–/– mice as described previously (55). Briefly, 
mice were deprived of water for 16 hours prior to glycerol administration. 
Mice were anesthetized with isoflurane and injected with either 50% glyc-
erol in water or saline as a control, 7.5 ml/kg body weight, with half the vol-
ume delivered into each anterior thigh muscle. Mice were sacrificed 1 day 
after injection, and kidneys were harvested for mRNA and protein analysis 
or embedded in paraffin for staining. Blood was collected via cardiac punc-
ture, and serum was isolated for creatinine measurement. Survival studies 
were performed in additional FtHPT+/+ and FtHPT–/– mice (n = 10 per group).
Serum iron, total iron-binding capacity, and urinary iron. Serum iron and total 
iron-binding capacity were measured using an Alfa Wassermann ACE Axcel 
clinical chemistry system (West Caldwell). Total urinary iron was measured 
with a Quantichrome iron assay kit (BioAssay systems) following the man-
ufacturer’s instructions. Catalytic iron was measured using previously 
described methods (18, 56).
Immunohistochemistry. Tissues were embedded in paraffin, sectioned, 
and stained with periodic acid-Schiff reagent (PAS) using standard 
protocols. For immunohistochemistry, paraffin-embedded 5-μm kid-
ney sections were deparaffanized in xylenes, rehydrated in a series 
of ethanol rinses from 100% to 70% ethanol, then washed in distilled 
water. Antigen retrieval was performed in Trilogy (Cell marque) at 
95°C for 30 minutes. Sections were allowed to cool slowly, washed 
in distilled water, and incubated in 3% H2O2 for 10 minutes. Sec-
tions were blocked in blocking buffer containing 5% goat serum in 
PBS, 0.1% Tween-20 (PBST), at room temperature for 1 hour. Pri-
mary antibodies were diluted in the blocking buffer for FtH (Santa 
Cruz Biotechnology; 1:200) or FPN (Abcam; 1:100) and added to sec-
tions overnight at 4°C. Sections were washed 3 times with PBST for 
5 minutes each. Goat anti-rabbit secondary antibody (Jackson 
Table 1
Primers for genotyping and real-time PCR analysis
Gene Primer sequence
Genotyping
FtH flox forward 5′-CCATCAACCGCCAGATCAAC-3′
FtH flox reverse 5′-CGCCATACTCCAGGAGGAAC-3′
FtH deletion forward 5′-GGCTGTTGTCCTGCTCTAAG-3′
Cre forward 5′-GCCAGGCGTTTTCTGAGCATAC-3′
Cre reverse 5′-CACCATTGCCCCTGTTTCACTATC-3′
Real-time PCR
FPN forward 5′-GTGGAGTACTTCTTGCTCTGG-3′
FPN reverse 5′-CTGCTTCAGTTCTGACTCCTC-3′
HO-1 forward 5′-GGTGATGGCTTCCTTGTACC-3′
HO-1 reverse 5′-AGTGAGGCCCATACCAGAAG-3′
GAPDH forward 5′-ATCATCCCTGCATCCACT-3′
GAPDH reverse 5′-ATCCACGACGGACACATT-3′
FtL forward 5′-CGTCTCCTCGAGTTTCAGAAC-3′
FtL reverse 5′-CTCCTGGGTTTTACCCCATTC-3′
FtH forward 5′-CCATCAACCGCCAGATCAAC-3′
FtH reverse 5′-GAAACATCATCTCGGTCAAA-3′
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150 mmol/l NaCl, 1 mmol/l EGTA, 1 mmol/l sodium orthovanadate, and 
1 mmol/l sodium fluoride) with protease inhibitor (Sigma-Aldrich) and 
quantified using BCA protein assay (Thermo Scientific). Total protein 
(10–15 μg for cells, 2 μl of urine, and 75 μg for tissues) was resolved on a 
12% Tris-glycine sodium dodecyl sulfate polyacrylamide gel electropho-
resis and transferred to a polyvinylidene fluoride membrane (Millipore). 
Membranes were blocked with 5% nonfat dry milk in PBST for 1 hour and 
then incubated with a rabbit anti-FtH antibody (Santa Cruz Biotechnol-
ogy, 1:5,000), a rabbit anti-SCL40A1 (FPN) antibody (Alpha Diagnostic; 
1:1,000), a rabbit anti-NRAMP2 (DMT-1) antibody (Santa Cruz Bio-
technology, 1:1,000), a rabbit anti–HO-1 antibody (Enzo LifeScienc-
es; 1:2,000), a rabbit anti–cleaved caspase-3 antibody (Cell Signaling; 
1:2,000), or a goat anti-NGAL antibody (R&D Systems; 1:2,000) followed 
by a peroxidase-conjugated goat anti-rabbit or -mouse IgG antibody or 
donkey anti-goat IgG antibody (Jackson ImmunoResearch Laboratories; 
1:10,000). Horseradish peroxidase activity was detected using an enhanced 
chemiluminescence detection system (GE Healthcare). The membrane 
was stripped and probed with anti-GAPDH antibody (Sigma-Aldrich; 
1:5,000) to confirm loading and transfer. Densitometry analysis was per-
formed, and results were normalized to GAPDH expression and expressed 
as fold change relative to controls. For FtL detection, samples were run 
on a native gel, transferred onto PVDF membrane, incubated with rab-
bit anti-FtL antibody (generated in house), followed by peroxidase-conju-
gated goat anti-rabbit antibody and detected using chemiluminescence, 
as described above. For transferrin and NGAL detection, 2 μl urine was 
resolved on a 12% Tris-glycine sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, transferred onto PVDF membrane, blocked, incubated 
with goat anti-NGAL antibody (1:2,000) or mouse anti-transferrin anti-
body (Santa Cruz Biotechnology; 1:1,000) followed by a peroxidase-con-
jugated goat anti-mouse IgG antibody or donkey anti-goat IgG antibody 
(Jackson ImmunoResearch Laboratories; 1:10,000), and detected using 
chemiluminescence as described above.
ELISA. ELISA analyses for ferritin (Kamiya Biomedical Co.), NGAL 
(Bioporto Diagnostics), and transferrin and hemopexin (Alpha Diag-
nostic) were performed on serum or urine following the manufacturer’s 
instructions. Urine creatinine was measured by LC-MS/MS (54). Data were 
expressed as micrograms per milliliter or were normalized to urine creati-
nine and expressed as micrograms per milligram creatinine.
Apoferritin and FtH treatment. Primary proximal tubular cells were isolated 
from wild-type mice as described previously (59) and immortalized by trans-
fection with an SV40 plasmid. Cells were treated at various doses and times 
with apoferritin (Sigma-Aldrich). Cell lysates treated with 0, 0.5, and 1.0 
mg/ml were collected in RIPA buffer containing protease inhibitor cocktail 
(Sigma-Aldrich) after 16 hours for Western blot analysis. Additionally, lysates 
treated with 1.0 mg/ml apoferritn were collected at time 0 and 8 hours in 
TRIzol for RNA analysis by real-time PCR as described above. Cells were 
treated with 0.5 mg/ml FtH or FtH-M (generated in house) for 16 hours and 
analyzed for FPN and FtH expression by Western blot as described above.
Polarization of proximal tubular cells and hepcidin treatment. Proximal tubular 
cells were plated on Transwell filters (Corning) with a pore size of 0.4 μm. 
Polarization was confirmed with immunocytochemistry for ZO-1 as pre-
viously described (60). Rat mAb R40.76 against ZO-1 was a gift from D.F. 
Balkovetz (University of Alabama at Birmingham, Birmingham, Alabama, 
USA). For hepcidin pretreatment, cells were treated with hepcidin (Pep-
tides International; 400 nM) for 48 hours prior to iron uptake assay.
Iron uptake assay. Cells were washed with PBS and media devoid of 
transferrin, and serum was added to both apical and basal compart-
ments. In the apical chamber, media was supplemented with 5 μM 55Fe 
(PerkinElmer), and 200 μmol/l ascorbic acid was added to the media in 
order to ensure that iron was in the ferrous state. After 2 hours, media 
ImmunoResearch Laboratories; 1:500) was diluted in blocking buffer 
and added to the sections for 1 hour at room temperature. Sections were 
washed 3 times with PBST for 5 minutes each. Chromagen substrates 
were mixed per the manufacturer’s instructions (Vector Labs) and added 
to sections. Sections were washed in distilled water, dehydrated, and 
mounted using xylene mounting media (PROTOCOL).
Immunohistochemical staining for FPN was also performed on kid-
ney sections from wild-type C57BL/6 mice. Kidneys were preserved by in 
vivo cardiac perfusion with PBS (pH 7.4) followed by periodate-lysine-2% 
paraformaldehyde (PLP), then cut transversely into several 2- to 4-mm-
thick slices and immersed for approximately 24 hours at 4°C in the same 
fixative. Kidney samples from each animal were embedded in polyester wax 
(polyethylene glycol 400 distearate [Polysciences], 10% 1-hexadecanol), and 
3-μm-thick sections were cut and mounted on triple chrome-, alum-, and 
gelatin-coated glass slides. Immunolocalization was accomplished using 
immunoperoxidase procedures described previously (57). Briefly, sections 
were dewaxed, rehydrated, and incubated in 3% H2O2 for 45 minutes to block 
endogenous peroxidase activity. Sections were blocked for 15 minutes with 
Serum-Free Protein Block (DakoCytomation), then incubated at 4°C over-
night with primary antibody. The sections were washed in PBS and incu-
bated for 30 minutes with polymer-linked, peroxidase-conjugated goat anti-
rabbit IgG (MACH2, Biocare Medical), again washed with PBS, then exposed 
to diaminobenzidine (DAB) for 5 minutes. Sections were washed in distilled 
water, dehydrated with xylene, mounted, and observed by light microscopy.
For lotus lectin staining, embedding, sectioning, deparrafinization, rehy-
dration, antigen retrieval, and peroxidase blocks were performed as above. 
Additionally, avidin/biotin blocking was performed using the avidin/biotin 
blocking kit (Vector Labs) per the manufacturer’s instructions. Biotinylated 
lotus lectin diluted 1:400 in PBS was added for 1 hour. Sections were washed 3 
times in PBS, then incubated in ABC ready-to-use reagent (Vector Labs) for 30 
minutes and washed again. Chromagen substrate was diluted per the manu-
facturer’s instructions (Vector Labs), and sections were washed, dehydrated, 
and mounted as above. Images were captured using a Leica DM IRB micro-
scope (Leica Microsystems) and Image-Pro Plus software (Media Cybernetics).
Immunoelectron microscopy. Immunoelectron microscopy was performed 
as previously described, with minor modifications (58). Briefly, tissue 
samples were preserved by in vivo cardiac perfusion with PBS followed 
by 2% paraformaldehyde-lysine-periodate (PLP) fixative and stored over-
night at 4°C. Samples were rinsed in PBS, treated with 0.1M NH4Cl, and 
then dehydrated in a graded series of ethanols, embedded in Lowicryl 
K4M (Electron Microscopy Sciences), and polymerized under UV light 
for 24 hours at –20°C and for 64 hours at room temperature. Ultra-
thin (60–70 nm) sections of samples containing well-preserved proxi-
mal tubules were cut and mounted on formvar/carbon-coated nickel 
grids. FPN localization was detected using immunogold cytochemistry. 
Briefly, sections were exposed to 0.1M NH4Cl and to 1% BSA to block 
nonspecific binding, treated with the anti-FPN antibody (Abcam; 1:25) 
overnight at 4°C, rinsed, treated with anti-rabbit secondary antibody 
conjugated to 0.8 nm colloidal gold (Aurion Ultrasmall Immunogold 
Conjugate, Electron Microscopy Sciences), washed, postfixed, washed, 
silver-enhanced (Aurion R-Gent SE-EM, Electron Microscopy Scienc-
es), washed, and counterstained with uranyl acetate. A negative con-
trol section was exposed to incubation buffer in place of the primary 
antibody. Sections were observed and imaged using a Hitachi H-7600 
transmission electron microscope (Hitachi High-Technologies America) 
equipped with a Macrofire monochrome progressive-scan CCD cam-
era (Optronics) and AMT image capture software (version 600.335h; 
Advanced Microscopy Techniques).
Western blot analysis. Harvested cells or collected tissues were lysed in 
RIPA buffer (50 mmol/l Tris/HCl, 1% NP-40, 0.25% deoxycholic acid, 
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from both the compartments was removed, and filters were washed at 
least 4 times with PBS. Cells were harvested in RIPA buffer, and radioactiv-
ity was measured in duplicates for each sample. The amount of iron in the 
cellular lysates was quantitated using a standard curve generated using 
known concentrations of 55Fe. Protein content in each sample was mea-
sured, and data were expressed as picomoles of 55Fe per milligram protein.
Statistics. Data are presented as mean ± SEM. Unpaired 2-tailed Stu-
dent’s t test was used for comparisons between 2 groups. For compari-
sons involving more than 2 groups, ANOVA and Newman-Keuls test were 
used. A P value less than 0.05 was considered significant. All experiments 
were performed at least 3 times.
Study approval. All procedures involving mice were performed in accordance 
with NIH guidelines for the use and care of live animals and were reviewed 
and approved by the IACUC of the University of Alabama at Birmingham.
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